RxDoctor Payments Data

Beth Kus, PA

Medical · Pittsburgh, PANPI 1972659217

Payments from drug & device makers

$3,740in general payments, 2019–2025

Across 114 payments — averaging $32.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Lundbeck LLC$338
  • Teva Pharmaceuticals USA, Inc.$328
  • Pfizer$299
  • Biohaven Pharmaceuticals, Inc.$247
  • Lilly USA, LLC$130
  • plus $256 from 3 others

What the payments were for

  • Food & beverage$3,740100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,740 in reported general payments places this provider in the 85th percentile of 2,594 medical providers in Pennsylvania.

See all medical providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$58,831
Medicare patients
46
Services billed
7,531

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant112$163,887
Ajovy AutoinjectorFremanezumab-Vfrm90$67,502
Nurtec OdtRimegepant Sulfate59$66,632
Emgality PenGalcanezumab-Gnlm68$54,424
Aimovig AutoinjectorErenumab-Aooe22$20,013
QuliptaAtogepant14$14,661
Ajovy SyringeFremanezumab-Vfrm20$14,089
Sumatriptan Succinate28$4,904
Topiramate103$2,385
Zonisamide57$1,281
Candesartan Cilexetil11$714
Nortriptyline Hcl24$486
RizatriptanRizatriptan Benzoate36$401
Duloxetine Hcl20$401
Prochlorperazine Maleate38$356

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$2,142$178,548126 claims
PfizerNurtec Odt$299$66,63259 claims
Lilly USA, LLCOlanzapine$130$3218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,594 medical providers in Pennsylvania.

Other medical in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →